SCHEMBL296952

SCHEMBL296952

O=C(O)c1nc2ccccc2c(O)c1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
MAPT P10636 1/20 0.63
DYRK1A Q13627 4/20 0.50
DHODH Q02127 3/20 0.50
PDE10A Q9Y233 3/20 0.50
PIM1 P11309 3/20 0.46
DYRK1B Q9Y463 3/20 0.45
CLK1 P49759 2/20 0.45
CDK9 P50750 2/20 0.45
DYRK2 Q92630 2/20 0.45
CLK4 Q9HAZ1 2/20 0.45
CDK5 Q00535 1/20 0.45
CLK2 P49760 1/20 0.45
GSK3B P49841 1/20 0.45
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
RNASEH1 O60930 1/20 0.45
ERCC1 P07992 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29849579 1.00 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2MAPTDYRK1ADHODH
SCHEMBL29402079 0.85 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MAPTDYRK1ADHODH
SCHEMBL1332157 0.85 MAP2K3 (0.50) ALDH1A1SMN1; SMN2MAPTDYRK1ADHODH
SCHEMBL6783762 0.85 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MAPTDYRK1ADHODH
SCHEMBL28149300 0.83 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2MAPTDYRK1ADHODH
SCHEMBL27775101 0.83 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2MAPTDYRK1ADHODH
SCHEMBL2908831 0.83 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2MAPTDYRK1ADHODH
SCHEMBL5388884 0.83 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2MAPTDYRK1ADHODH
SCHEMBL6079236 0.82 HDAC8 (0.48) ALDH1A1SMN1; SMN2MAPTDHODHPDE10A
SCHEMBL31109172 0.82 SMN1; SMN2 (0.55) ALDH1A1SMN1; SMN2MAPTDYRK1ADHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023246355-A1 GINKGO LEAF ORGANIC ACID EXTRACT, METHOD FOR PREARING SAME AND USE THEREOF 浙江康恩贝制药股份有限公司 2023-12-28 WO claimed
CN-117089040-A Aqueous polyurethane-urea emulsion modified based on aniline trimer and epoxy resin and preparation method thereof 西华大学 2023-11-21 CN claimed
CN-115078588-B Aspongopus and quality evaluation method of processed product thereof 江阴天江药业有限公司 2023-07-07 CN claimed
CN-114624343-B Method for relatively quantifying 45 inflammations and immune metabolites in serum 中国科学院大连化学物理研究所 2023-01-24 CN claimed
CN-115078588-A Aspongopus and quality evaluation method of processed product thereof 江阴天江药业有限公司 2022-09-20 CN claimed
CN-114624343-A Method for relative quantification of 45 inflammations and immune metabolites in serum 中国科学院大连化学物理研究所 2022-06-14 CN claimed
CN-110423283-B Water-based nitrocotton, emulsion thereof and preparation method thereof 西华大学 2021-09-07 CN claimed
CN-110078883-B Water-based paint resin based on konjac flour, preparation method and composition thereof 西华大学 2021-08-03 CN claimed
CN-110437678-B Energy-saving environment-friendly water-based paint and preparation method thereof 西华大学 2021-04-27 CN claimed
CN-110423520-A A kind of environment-friendly water-based glass coating and preparation method thereof SICHUAN YIBIN GLOBAL GELASI GLASS MFG CO LTD 2019-11-08 CN claimed
US-20100041756-A1 METHOD OF MODULATING B CELL FUNCTIONING IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY & MEDICINE (GB) 2010-02-18 US claimed
EP-1824469-A4 A METHOD OF MODULATING B CELL FUNCTIONING NUON THERAPEUTICS PTY LTD (AU) 2008-07-30 EP claimed
CN-101232878-A Method of modulating T cell functioning UNIV LELAND STANFORD JUNIOR (US) 2008-07-30 CN claimed
EP-1845967-A4 A METHOD OF MODULATING T CELL FUNCTIONING UNIV LELAND STANFORD JUNIOR (US) 2008-03-05 EP claimed
US-20080009519-A1 METHOD OF MODULATING T CELL FUNCTIONING ANGIOGEN PHARMACEUTICALS PTY LIMITED (AU) 2008-01-10 US claimed
CN-101098687-A Methods of modulating B cell function ANGIOGEN PHARMACEUTICALS PTY L (AU) 2008-01-02 CN claimed
EP-1845967-A2 A METHOD OF MODULATING T CELL FUNCTIONING The Board of Trustees of Leland Stanford Junior University (US) 2007-10-24 EP claimed
EP-1824469-A1 A METHOD OF MODULATING B CELL FUNCTIONING Angiogen Pharmaceuticals Pty. Ltd (AU) 2007-08-29 EP claimed
WO-2006076580-A2 A METHOD OF MODULATING T CELL FUNCTIONING THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2006-07-20 WO claimed
WO-2006053390-A1 A METHOD OF MODULATING B CELL FUNCTIONING ANGIOGEN PHARMACEUTICALS PTY. LTD. (AU) 2006-05-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009519-A1 METHOD OF MODULATING T CELL FUNCTIONING IFNG, CD4, IDO1 ALDH1A1 1352/4885SMN1; SMN2 4156/4885MAPT 3672/4885
US-20100041756-A1 METHOD OF MODULATING B CELL FUNCTIONING KYNU, IDO1, IDO2 ALDH1A1 1104/4885SMN1; SMN2 4850/4885MAPT 4146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.